Global Melanoma Treatment Market Poised to Surpass $12 Billion by 2028, Driven by Advances in Immunotherapy and Targeted Therapies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Melanoma Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering.

The global market for melanoma treatment was estimated to reach $6.8 billion in 2022 and is expected to reach $12.1 billion through 2028, growing at a CAGR of 10.2% during the forecast period.

Major players in the market include Merck & Co., Bristol Myers Squibb and Novartis. Apart from the major players there are also small biotech companies such as Erasca, HUYABIO International and IO Biotech that have promising drug candidates in the pipeline, which should push market growth during the forecast period.

Growth Drivers:

The analysis disclosed in this publication stresses the instrumental role of modern medical interventions, such as the introduction of immune-checkpoint inhibitors and small molecule-targeted therapies, in revolutionizing the treatment landscape for advanced melanoma. With a compound annual growth rate (CAGR) of 10.2% projected from 2022 through 2028, the melanoma treatment sector is witnessing an uptrend, underpinned by increasing drug approvals and surging patient survival rates. Biotechnological innovations and strategic initiatives by industry leaders compound the market expansion.

Regional Insights:

The North American melanoma treatment sector emerges as the frontrunner, closely trailed by Europe, accounting for the lion's share of the global market. Factors spurring growth in these regions include heightened healthcare expenditure, public awareness campaigns, and supportive government frameworks. In particular, immunotherapies dominate the therapeutics segment, claiming the majority market share in 2022.

Vital Segmentation:

The research delves into the segmentation of the melanoma treatment market by treatment type, cancer stage, and therapeutics. The localized stage of melanoma garners considerable attention due to the high success rates of surgical interventions, which remain the primary treatment approach.

Pipeline Analysis:

With a spotlight on the promising treatment pipeline, the publication highlights the continuous emergence of first-in-class molecules targeting novel aspects of melanoma. A burgeoning focus on personalized medicine, epitomized through innovative cell therapies and vaccines, showcases a commitment to tackling disease recurrence and improving patient outcomes.

Market Dynamics:

The report articulates the dual forces shaping the melanoma treatment marketplace, identifying critical stimulants such as technological progressions, enhanced detection tools, and patient advocacy. Conversely, challenges like the high costs of cutting-edge treatments and regulatory hurdles are acknowledged as potential market constraints.

Key Players:

Spotlighting the change-makers, the research profiles leading organizations and emerging biotech firms that are catalyzing paradigm shifts in melanoma therapeutics. These entities are pioneering the development of groundbreaking treatments, consequently fortifying their market position.

The report profiles the following leading players

• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Erasca
• F. Hoffmann-La Roche
• Huyabio International
• Iovance Biotherapeutics
• IO Biotech
• Merck & Co. Inc.
• Moderna Ina.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals

Key Attributes:

Report Attribute	Details
No. of Pages	131
Forecast Period	2023 - 2028
Estimated Market Value (USD) in 2023	$7.4 Billion
Forecasted Market Value (USD) by 2028	$12.1 Billion
Compound Annual Growth Rate	10.2%
Regions Covered	Global

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

• Risk Factors, Causes and Prevention
• Symptoms
• Pathophysiology and Clinical Subtypes
• Prognosis
• Epidemiology
• Diagnosis
• Biopsy
• Laboratory Tests
• Blood Tests
• Imaging Tests
• Treatment
• Immunotherapy
• PD-1 and PD-L1 Inhibitors
• CTLA-4 inhibitors
• LAG-3 Inhibitors
• Interleukin-2 (IL-2, Proleukin)
• Virus Therapy
• BRAF inhibitors:
• MEK Inhibitors

Chapter 4: Market Dynamics

• Market Factors
• Market Drivers
  • Increasing Prevalence of Melanoma
  • Technological Advancements and Product Launches
  • Strategic Initiatives
  • Developments in Early Detection Tools
  • Patient Advocacy Groups and Awareness
• Market Restraints
  • High Cost of Treatment
  • Stringent Regulations
  • Resistance to Therapies
• Market Opportunities

Chapter 5: Market Breakdown by Type

• Surgery
• Wide Excision
• Mohs Surgery
• Amputation
• Lymph Node Dissection
• Therapeutics
• Therapeutics by Type
• Radiation Therapy

Chapter 6: Market Breakdown by Disease Stage

• Localized Disease
• Regional Disease
• Distant Disease

Chapter 7: Market Breakdown by Region

Chapter 8: Sustainability: An ESG Perspective

• ESG Challenges in the Pharmaceutical Industry
• ESG Practices in the Market for Melanoma Therapeutics
• Case Study
• Research Viewpoint

Chapter 9: Emerging Technologies/ Developments

• Novel Immune Checkpoint Inhibitors
• Adoptive Cell Therapy
• Engineered TCR Therapy
• Vaccines
• Targeted Therapy

Chapter 10: Regulatory Landscape and Pipeline Analysis

Chapter 11: Patent Analysis

Chapter 12: Competitive Landscape

Chapter 13: Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/i3kz5h

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.